DRMA vs REVB

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 15, 2026

DRMA

37.3
AI Score
VS
REVB Wins

REVB

39.6
AI Score

Investment Advisor Scores

DRMA

37score
Recommendation
SELL

REVB

40score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric DRMA REVB Winner
Net Income -4.81M -6.33M DRMA
Operating Income -4.94M -6.75M DRMA
ROE -138.0% -62.9% REVB
ROA -90.5% -50.7% REVB
Total Assets 5.32M 12.50M REVB
Cash 4.41M 11.48M REVB
Current Ratio 3.40 6.21 REVB
Free Cash Flow -5.01M -5.88M DRMA

Relative Price Performance (Last 90 Days)

DRMA 1M: +12.7% · 3M: +14.5% REVB 1M: +1.9% · 3M: +0.9%

Current Technical Phase

DRMA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (0.7% over 20 days), RSI 57

RSI (14): 57.1 · Price: $1.42

REVB

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (1.1% over 20 days), RSI 51

RSI (14): 50.6 · Price: $1.09

Fundamentals Snapshot

Metric DRMA REVB
Market Cap
Forward P/E -1.0 -0.4
Trailing P/E 0.0
Revenue (TTM)
Revenue Growth 0.0% 0.0%
Gross Margin
Operating Margin 0.0% 0.0%
EPS -4.20 27.03
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, REVB is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.